Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 266

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 2
Chunk 266
---
 civil conspiracy and seeks, inter alia, equitable relief, including, but not limited to,
return to the Company any shares received in connection with the merger, and damages. On October 1, 2024, the defendants moved to dismiss
the complaint. A hearing took place on June 25, 2025 and the Court took defendants’ motion under advisement.

Renovaro, Inc. (“Renovaro”)
commenced an action against Predictive Oncology, Inc. (“POAI”) in the Delaware Court of Chancery claiming that POAI breached
a “definitive” January 2025 Letter Agreement pursuant to which Renovaro was going to acquire POAI. As a result of its breach,
POAI made that acquisition impossible and dramatically devalued the share price of stock Renovaro had already acquired as well as the
value of the company it was contractually entitled to acquire. Renovaro sought specific perfo1mance or, in the alternative, money damages.
The parties have exchanged paper discovery and noticed depositions. The action has been held in abeyance while the parties attempt to
negotiate a settlement.

Item 4. Mine Safety Disclosures.

Not applicable.

54

PART II

Item 5. Market for Registrant’s Common Equity,
Related Stockholder Matters and Issuer Purchases of Equity Securities 

Market Information and Holders of our Common Stock

Our Common Stock trades on the
Nasdaq Capital Market under the symbol “RENB”.

As of September 26, 2025, the
Company had 231,802,470 shares of Common Stock issued and approximately 233 stockholders of record. The actual number of stockholders
is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street
name by brokers and other nominees.

Recent Sales of Unregistered Securities

 None.

Company Purchases of Equity Securities

None.

Dividends

The Company has not declared or
paid any cash dividends on its Common Stock and does not intend to declare or pay any cash dividends in the foreseeable future. The payment
of dividends, if any, is within the discretion of the Board and will depend on the Company’s earnings, if any, its capital requirements
and financial condition and such other factors as the Board may consider.

Item 6. [Reserved]

Item 7. Management’s Discussion and Analysis of Financial Condition
and Results of Operations

The following discussion of